Demographic and clinical characteristics
| Full cohort (n=3283) | Subjects ever tested for gonorrhoea/chlamydia (n=1434) | Subjects ever positive on gonorrhoea/chlamydia testing (n=80) | |
| Gender | |||
| Male | 2123 (65) | 685 (48) | 53 (66) |
| Female | 1160 (35) | 749 (52) | 27 (34) |
| Age in first year of study time, years | |||
| Median (IQR) | 40 (35–46) | 39 (33–44) | 33 (27–39) |
| 18–29 | 358 (11) | 220 (15) | 28 (35) |
| 30–39 | 1258 (38) | 591 (41) | 35 (44) |
| 40–49 | 1247 (38) | 510 (36) | 16 (20) |
| ≥50 | 420 (13) | 113 (8) | 1 (1) |
| Race/ethnicity | |||
| African-American | 2579 (79) | 1200 (84) | 71 (89) |
| White | 627 (19) | 205 (14) | 9 (11) |
| Hispanic (non-African-American) | 50 (2) | 21 (1) | 0 |
| Other/unknown | 27 (1) | 8 (1) | 0 |
| HIV risk factors | |||
| IDU | 687 (21) | 261 (18) | 9 (11) |
| IDU heterosexual | 621 (19) | 294 (21) | 11 (14) |
| IDU MSM | 138 (4) | 46 (3) | 4 (5) |
| Heterosexual | 1002 (31) | 537 (37) | 20 (25) |
| MSM | 659 (20) | 224 (16) | 32 (40) |
| Unknown/other | 176 (5) | 72 (5) | 4 (5) |
| Mean visits/year over all years in care* | |||
| Median (IQR) | 4 (3–6) | 5 (4–6) | 4 (3–6) |
| <3 | 693 (21) | 219 (15) | 16 (20) |
| 3–6 | 1848 (56) | 862 (60) | 53 (66) |
| >6 | 742 (23) | 353 (25) | 11 (14) |
| Mean CD4 cell count in first year of study time (cells/mm3) | |||
| Median (IQR) | 308 (150–501) | 333 (170–516) | 369 (263–568) |
| ≤200 | 1096 (33) | 418 (29) | 15 (19) |
| 201–350 | 751 (23) | 336 (23) | 21 (26) |
| >350 | 1436 (44) | 680 (47) | 44 (55) |
| Mean HIV-1 RNA in first year of study time | |||
| Median (IQR) (log10 copies/ml) | 4.1 (2.8–4.8) | 4.1 (2.9–4.8) | 4.0 (3.0–4.6) |
| ≤400 copies/ml | 718 (22) | 297 (21) | 12 (15) |
| 401–9999 copies/ml | 804 (24) | 375 (26) | 29 (36) |
| ≥10 000 copies/ml | 1722 (52) | 748 (52) | 39 (49) |
| Missing | 39 (1) | 14 (1) | 0 |
| Syphilis testing | |||
| Ever tested | 2487 (76) | 1196 (83) | 66 (83) |
| Never tested | 796 (24) | 238 (17) | 14 (18) |
Values are number (%) unless specified. Percentages may exceed 100 due to rounding.
* Only visits to HIV and/or gynaecological providers included.
IDU, injection drug user; MSM, men who have sex with men.